the European trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA trial).

Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4·2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat. Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% CI 9–29, p=0·0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated. Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease

Overview of JET results

High density and high confinement operation in ELMy H-mode is confirmed at or above the normalized parameters foreseen for the ITER operating point (H98(y,2) 3c 1, n/nGW 3c 1, \u3b2N > 1.8 at q95 3c 3). The scaling of the ELMy H-mode with \u3b2N could be more favourable than that predicted by the IPB98(y,2) scaling. In ELMy H-mode, ion cyclotron current drive (ICCD) control of large sawteeth stabilized by fast particle has been demonstrated and the underlying neo-classical tearing modes (NTMs) and sawtooth physics is being refined. At high-density, Type I ELMy H-modes show trends that would lead to marginally acceptable ELMs on ITER. Type II ELM regime has been produced, though under very restrictive conditions. Type III ELMy operation with radiation fractions up to 95% has been demonstrated by seeding of N2 in H-modes and could extrapolate to Q = 10 ITER operation, albeit at high current (17 MA). The mitigation of Type I ELMs, nevertheless, remains a challenge. Considerable progress has been obtained in internal transport barrier (ITB) plasmas, with operation at central densities close to the Greenwald density or/and low toroidal rotation or/and high triangularity. Demonstrations of full current drive and successful simultaneous real time control of safety factor and temperature profiles have been achieved in ITB plasmas. Physics of resistive wall modes (RWMs) has been compared with theory, showing favourable scaling for ITER. High \u3b2N 3c 2.8 operation of hybrid modes (also called improved H-modes) has been obtained with dominant neutral beam heating. Hybrid modes with dominant ion cyclotron resonance heating (ICRH) have also been achieved. Trace tritium experiments yielded valuable information on particle transport in H-mode, ITB and hybrid regimes. In Type I ELMy plasmas, successful tests of the conjugate-T ICRH scheme have been achieved as well as lower hybrid coupling at ITER-relevant 10\u201311 cm distances. Reduced D and T fuel retention has been observed, which could relate to operation with vertical targets in the divertor and/or lower (ITER-like) vessel temperature. It is confirmed that erosion occurs predominantly on the main chamber surfaces, with possible benefits for T retention in ITER, although consequences for the metallic first wall lifetime need to be assessed. Disruption and ELM studies indicate that transient power deposition could be less constraining than expected for the ITER divertor, but more challenging for the metallic first wall. Alpha particle tomography and direct observation of alpha particle slowing down have been made possible by \u3b3 -spectroscopy. Measurements of Alfve \u301n cascades have been improved by a new interferometric technique. Promising tests of ITER relevant neutron counting detectors have been conducted

The European Trial On Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease

Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4·2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat. Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% β blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% Cl 9–29, p=0·0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated. Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease